BIB Stock Overview
ProShares Trust - ProShares Ultra Nasdaq Biotechnology is an exchange traded fund launched and managed by ProShare Advisors LLC.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
ProShares Trust - ProShares Ultra Nasdaq Biotechnology Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$56.43 |
52 Week High | US$62.45 |
52 Week Low | US$40.10 |
Beta | 0 |
1 Month Change | -3.83% |
3 Month Change | 2.51% |
1 Year Change | 9.02% |
3 Year Change | -31.33% |
5 Year Change | 1.71% |
Change since IPO | 651.27% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
BIB | US Capital Markets | US Market | |
---|---|---|---|
7D | 0.7% | 2.4% | 2.1% |
1Y | 9.0% | 34.5% | 30.4% |
Return vs Industry: BIB underperformed the US Capital Markets industry which returned 36.2% over the past year.
Return vs Market: BIB underperformed the US Market which returned 31.1% over the past year.
Price Volatility
BIB volatility | |
---|---|
BIB Average Weekly Movement | 4.9% |
Capital Markets Industry Average Movement | 3.3% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BIB has not had significant price volatility in the past 3 months.
Volatility Over Time: BIB's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | n/a | n/a | https://www.proshares.com/funds/bib.html |
ProShares Trust - ProShares Ultra Nasdaq Biotechnology is an exchange traded fund launched and managed by ProShare Advisors LLC. It invests in public equity markets of the United States. It invests through derivatives in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors.
ProShares Trust - ProShares Ultra Nasdaq Biotechnology Fundamentals Summary
BIB fundamental statistics | |
---|---|
Market cap | US$101.57m |
Earnings (TTM) | US$0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs BIB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BIB income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$0 |
Earnings | US$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did BIB perform over the long term?
See historical performance and comparison